Product Description
Golimumab is a human IgG1 kappa monoclonal antibody derived from HuMab transgenic mice immunized with human tumor necrosis factor alpha (TNF-?). This antibody targets and neutralizes soluble as well as transmembrane human TNF-?, which plays a key role in chronic inflammatory diseases such as Rheumatoid arthritis, inflammatory bowel disease, Crohns disease, Psoriatic arthritis, and ankylosing spondylitis. Golimumab was developed by Janssen Biotech and received FDA approval in 2009 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and ankylosing spondylitis (AS). Additionally, in 2013, this antibody received approval for the treatment of ulcerative colitis. Golimumab is marketed under the trade name SIMPONI®
Biovision | A2141 | Anti-TNF-? (Golimumab), Human IgG1 Antibody DataSheet
Antibody Target: TNF-?
Target Alternative Name: CNTO 148, CNTO-148, Simponi ARIA, Simponi, TNFSF2, TNF-alpha, TNFA, TNF-?, TNF?
Tag Line: Golimumab is a human monoclonal antibody that binds and inhibits soluble and transmembrane human TNF-? that plays a central role in inflammatory diseases such as Rheumatoid Arthritis, Psoriatic Arthritis, and ankylosing spondylitis (AS)
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Golimumab
Accession #: DB06674
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE